Medifast (FRA:MDF) ROE % Adjusted to Book Value: -8.13% (As of Mar. 2026)


FRA:MDF Medifast Inc FRA:MDF
70 GF Score
Price €8.44
GF Value €7.03
Valuation Modestly Overvalued
! 2 Warning Signs
View Full Analysis

What is Medifast ROE % Adjusted to Book Value?

Medifast FRA:MDF -7.25% 70 ROE % Adjusted to Book Value is -8.13% as of Mar. 2026. GuruFocus rates FRA:MDF with a GF Score™ of 70/100 and a GF Value™ of €7.03 (Modestly Overvalued). The stock has 2 warning signs investors should review.

Medifast's ROE % for the quarter that ended in Mar. 2026 was -4.31%. Medifast's PB Ratio for the quarter that ended in Mar. 2026 was 0.53. Medifast's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2026 was -8.13%.

Medifast ROE % Adjusted to Book Value Related Terms

Medifast ROE % Adjusted to Book Value Historical Data

* Premium members only.

The historical data trend for Medifast's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Medifast ROE % Adjusted to Book Value Chart

Medifast Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROE % Adjusted to Book Value
Get a 7-Day Free Trial Premium Member Only Premium Member Only 7.82 10.59 15.25 1.14 -15.38

Medifast Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROE % Adjusted to Book Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.06 6.72 -6.21 -62.66 -8.13

FRA:MDF vs RGS, VGES, EVTK: ROE % Adjusted to Book Value Comparison

For the Personal Services subindustry, Medifast's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Medifast ROE % Adjusted to Book Value vs Personal Services Industry

For the Personal Services industry and Consumer Cyclical sector, Medifast's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Medifast's ROE % Adjusted to Book Value falls into.


FRA:MDF
70GF Score
Medifast Inc FRA:MDF
ROE % Adjusted to Book Value is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Medifast ROE % Adjusted to Book Value Calculation

Medifast's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2025 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-8.61% / 0.56
=-15.38%

Medifast's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2026 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-4.31% / 0.53
=-8.13%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a ROE % Adjusted to Book Value of -8.13% mean?
Medifast (FRA:MDF) has a ROE % Adjusted to Book Value of -8.13% as of Mar. 2026. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Medifast and its competitors.
Is Medifast's ROE % Adjusted to Book Value too high?
Medifast's current ROE % Adjusted to Book Value is -8.13%. Overall, Medifast has a GF Score™ of 70/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Medifast's ROE % Adjusted to Book Value compare to RGS and VGES?
Medifast's ROE % Adjusted to Book Value of -8.13% can be compared against companies in the Personal Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % Adjusted to Book Value for a Personal Services company?
A good ROE % Adjusted to Book Value depends on the Personal Services industry context. However, ROE % Adjusted to Book Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % Adjusted to Book Value mean?
A high ROE % Adjusted to Book Value can signal that a stock is expensive relative to its fundamentals. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Medifast and its competitors. Medifast's current ROE % Adjusted to Book Value is -8.13%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medifast stock overvalued right now?
Based on GuruFocus' analysis, Medifast (FRA:MDF) is currently considered Modestly Overvalued. The stock's GF Value™ is €7.03, compared to a current price of €8.44 — trading 20.1% above its estimated fair value. The current ROE % Adjusted to Book Value is -8.13%. Medifast's overall GF Score™ is 70/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % Adjusted to Book Value calculated?
ROE % Adjusted to Book Value is calculated from a company's financial statements. For Medifast (FRA:MDF), the current ROE % Adjusted to Book Value is -8.13% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Medifast (FRA:MDF) Overvalued in 2026?

Based on GuruFocus' analysis, Medifast stock appears to be overvalued. The current stock price of €8.44 is trading 20.1% above its estimated GF Value™ of €7.03. GuruFocus considers Medifast to be Modestly Overvalued.

Key valuation signals for FRA:MDF:

  • ROE % Adjusted to Book Value: -8.13%
  • GF Value™: €7.03 vs. price of €8.44 (20.1% above fair value)
  • GF Score™: 70/100 with 2 warning signs

No single metric tells the full story. See the FRA:MDF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Medifast Business Description

Other Exchanges MED:USA0K05:UKMDF:Germany
Address 100 International Drive, Baltimore, MD, USA, 21202
Medifast Inc is a old health and wellness company known for its habit-based and coach-guided lifestyle solution OPTAVIA, which provides people with a simple, yet comprehensive approach to address obesity and support a healthy life. The company provides unparalleled coaching support along with community, tailored nutrition and healthy habits, and empowers people to master their weight loss journey through each stage of life. The company has access to GLP-1 medications where clinically appropriate. The company is focused on offering talent to Lifelong Transformation, Making a Healthy Lifestyle Second Nature.
70GF Score

Get the complete analysis for FRA:MDF

ROE % Adjusted to Book Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€8.44
Price
€7.03
GF Value